Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and Co BDR | B3 | Healthcare | Pharmaceuticals | R$3.87T | 62.3x | 0.61 | R$144.57 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson BDR | B3 | Healthcare | Pharmaceuticals | R$2.18T | 17x | -0.45 | R$60.05 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie DRC | B3 | Healthcare | Pharmaceuticals | R$1.77T | 70.9x | -6.02 | R$62.58 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk AS | B3 | Healthcare | Pharmaceuticals | R$1.66T | 18.5x | 0.86 | R$45.89 | -5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | B3 | Healthcare | Pharmaceuticals | R$1.24T | 29.9x | 1.59 | R$65.38 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis AG DRC SA | B3 | Healthcare | Pharmaceuticals | R$1.23T | 18.6x | -0.97 | R$64.62 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck Co Inc BDR | B3 | Healthcare | Pharmaceuticals | R$1.13T | 11.3x | 0 | R$57 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen Inc BDR | B3 | Healthcare | Pharmaceuticals | R$890.76B | 37.1x | -0.95 | R$59.20 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences DRC | B3 | Healthcare | Pharmaceuticals | R$768.05B | 276.3x | -2.94 | R$309.12 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vertex Pharmaceuticals DRC | B3 | Healthcare | Pharmaceuticals | R$733.37B | -234.2x | 2.02 | R$717.59 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer Inc BDR | B3 | Healthcare | Pharmaceuticals | R$732.93B | 15.5x | 0.05 | R$32.24 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb Company BDR | B3 | Healthcare | Pharmaceuticals | R$585.29B | -11.2x | 0.05 | R$287 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
McKesson | B3 | Healthcare | Pharmaceuticals | R$506.82B | 31.4x | -24.28 | R$1,020 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GlaxoSmithKline | B3 | Healthcare | Pharmaceuticals | R$422.93B | 21.3x | -0.42 | R$42.04 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zoetis | B3 | Healthcare | Pharmaceuticals | R$383.74B | 26.8x | 3.4 | R$57.64 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Takeda Pharmaceutical Co | B3 | Healthcare | Pharmaceuticals | R$263.44B | 31.7x | 2 | R$87.17 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cardinal Health | B3 | Healthcare | Pharmaceuticals | R$190.32B | 23.8x | 0.26 | R$727.42 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alnylam Pharmaceuticals DRC | B3 | Healthcare | Pharmaceuticals | R$175.64B | -104.7x | -2.88 | R$67.99 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen DRC | B3 | Healthcare | Pharmaceuticals | R$99.27B | 10.3x | 0.26 | R$116 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Teva Pharmaceutical Industries DRC | B3 | Healthcare | Pharmaceuticals | R$91.47B | -9.5x | 0.05 | R$42.29 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biomarin | B3 | Healthcare | Pharmaceuticals | R$66.20B | 26x | 0.17 | R$208.72 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Incyte | B3 | Healthcare | Pharmaceuticals | R$64.55B | 354.1x | -3.66 | R$209 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Perrigo Company | B3 | Healthcare | Pharmaceuticals | R$19.72B | -24.2x | 0.02 | R$146.55 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hypera | B3 | Healthcare | Pharmaceuticals | R$12.61B | 9.3x | -0.51 | R$19.86 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.4% Upside | Upgrade to Pro+ | |
Hypera SA ON | B3 | Healthcare | Pharmaceuticals | R$12.51B | 9.4x | -0.51 | R$19.78 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23% Upside | Upgrade to Pro+ | |
Blau Farmaceutica | B3 | Healthcare | Pharmaceuticals | R$2.27B | 10.5x | -0.79 | R$13.04 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.5% Upside | Upgrade to Pro+ | |
Ouro Fino Saude Animal Particip | B3 | Healthcare | Pharmaceuticals | R$1.23B | 9.1x | 0.02 | R$22.77 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -7.9% Downside | Upgrade to Pro+ | |
PROFARMA ON | B3 | Healthcare | Pharmaceuticals | R$896.28M | 7.8x | 0.12 | R$7.38 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CM Hospitalar | B3 | Healthcare | Pharmaceuticals | R$391.60M | -0.3x | 0 | R$1.28 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |